NEWS , Press release 2021.12.16 Rebirthel and Otsuka Sign Licensing Agreement for iPSC-derived CAR-T / TCR-T Production Technology

Rebirthel Co., Ltd. announces that it entered into an exclusive commercial licensing agreement with Otsuka Pharmaceutical Co., Ltd. for our technologies on CAR-T/TCR-T genetically engineered cell production using induced pluripotent stem (iPS) cells. The agreement covers multiple therapeutic areas worldwide. For details, please refer to the attached press release.